Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 160928, 11 pages
http://dx.doi.org/10.1155/2015/160928
Review Article

Emerging Role of PACAP as a New Potential Therapeutic Target in Major Diabetes Complications

1Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
2Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
3Semel Institute, Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA

Received 12 January 2015; Revised 31 March 2015; Accepted 7 April 2015

Academic Editor: Janaka Karalliedde

Copyright © 2015 Rubina Marzagalli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Enduring diabetes increases the probability of developing secondary damage to numerous systems, and these complications represent a cause of morbidity and mortality. Establishing the causes of diabetes remains the key step to eradicate the disease, but prevention as well as finding therapies to ameliorate some of the major diabetic complications is an equally important step to increase life expectancy and quality for the millions of individuals already affected by the disease or who are likely to develop it before cures become routinely available. In this review, we will firstly summarize some of the major complications of diabetes, including endothelial and pancreatic islets dysfunction, retinopathy, and nephropathy, and then discuss the emerging roles exerted by the neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) to counteract these ranges of pathologies that are precipitated by the prolonged hyperglycemic state. Finally, we will describe the main signalling routes activated by the peptide and propose possible future directions to focus on developing more effective peptide-based therapies to treat the major complications associated with longstanding diabetes.

1. Introduction

The prevalence of diabetes is increasing worldwide. According to the World Health Organization (WHO), the total number of people affected by diabetes is expected to rise to an estimated 300 million cases by the year 2025 [1]. The onset of diabetes immediately increases the possibility for the patient to develop a broad spectrum of irreversible complications [2]. Both type 1 [3] and type 2 [4] diabetes have devastating consequences especially on small and large blood vessels. A considerable effort has been put into finding treatments for this condition and its complications. Among them, targeting endogenous peptidergic systems or their downstream signalling mechanisms is emerging as a valuable therapeutic option.

In this review we will outline some of the most recent advances from our research group and others in relationship to the role of a promising neuropeptide candidate endowed with potential beneficial effects to treat or ameliorate certain aspects of diabetes, namely, the pituitary adenylate cyclase-activating polypeptide (PACAP). We will emphasize how the neuropeptide interferes and in some cases prevents the development of specific pathological consequences of the disease, such as micro- and macroangiopathy, retinal dysfunction, and defective pancreatic β-cell insulin secretion, and discuss the major intracellular events implicated and how these are hampered by peptide treatment. The final purpose will be to shed more light into PACAP function for future exploitation in therapies aimed at arresting or preventing the development of complications associated with disease progression.

2. Diabetes and Its Complications

The term diabetes mellitus indicates a group of metabolic disorders characterized by high blood sugar and impaired insulin signaling. The disease is usually classified into type 1 diabetes, type 2 diabetes, and other specific types including gestational diabetes. Type 1 diabetes, also known as insulin-dependent diabetes, represents about 5–10% of all cases of diabetes. It is characterized by β-pancreatic cells destruction that leads to absolute insulin deficiency. This failure to produce insulin can be autoimmune-mediated or idiopathic. Type 2 diabetes constitutes 90–95% of all diabetes cases and results from insulin resistance, inadequate compensatory insulin secretory response, or both. It is characterized by reduced responsiveness of peripheral cells in the body to insulin and, consequently, reduced ability to transfer glucose out of the circulation [5]. Complications of diabetes can be largely divided into microvascular and macrovascular complications. The microvascular complications include diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy. The macrovascular complications include cerebrovascular disease, coronary heart disease, and peripheral vascular disease (summarized in Table 1).

Table 1: Main complications associated with longstanding diabetes.

Elevated glucose levels result in an increased production of reactive oxygen species (ROS) and inflammatory mediators strictly involved in vasculature dysfunction. The altered system not only causes hypertension, ischemia, and/or altered vascular permeability but also contributes to other complications of diabetes [6, 7].

In the last decades, a big effort was put into finding new therapeutic approaches to target either the full range of diabetic complications or the damaged tissues/organs. Although several classes of antidiabetic drugs are currently available, achieving and maintaining long-term glycemic control are often challenging and not sufficient alone, so a significant need for novel antidiabetic drugs remains. It has been discovered that neuropeptides and their analogues, activating different signalling pathways through their receptors, are emerging as new therapeutic options. Among these, one of the most promising human peptides is the pituitary adenylate cyclase-activating polypeptide (PACAP). This review outlines the knowledge accumulated over the past years on the role of this neuropeptide in the major complications of diabetes, particularly emphasizing its potential for new therapeutic approaches.

3. PACAP, Receptors, and Functions

PACAP (molecular formula ; for details on PACAP38 chemical structure please refer to Figure 1) was originally isolated from an ovine hypothalamus extract [8]. Two PACAP isoforms have been identified, a 38-amino-acid form (PACAP38) and a C-terminally truncated 27-amino-acid form (PACAP27). It belongs to the secretine, glucagon, and peptide histidine-isoleucine (PHI) superfamily and binds to an overlapping group of receptors. PACAP receptors are G protein-coupled receptors and can be classified into two main groups, PAC1 and VPAC (including VPAC1 and VPAC2 subtypes), both of which activate adenylate cyclase with consequent stimulation of cAMP production and IP accumulation [9, 10]. In distinct cell types, PACAP is able to trigger different pathways, depending on which receptor splice variants are expressed, peptide concentration being used, and other biological factors. Among PACAP functions, the one that mostly emerges is its strong cytoprotective role, promoting survival in many types of neuronal and nonneuronal cells and tissues, including lymphocytes, chondrocytes, endothelial cells, Schwann cells, liver, lung, and ovary [1117]. In vitro and in vivo studies have shown that the peptide acts through the PAC1 receptors to stimulate various downstream executors of the protein kinase A and C (PKA and PKC) pathways [1821]. It also activates ion channels, β-arrestin signalling, and mitogen-activated protein (MAP) kinase in some tissues [22, 23]. PACAP and its receptors have been detected in multiple organs, with the highest levels in endocrine glands and in the central nervous system. Lower expression has been identified in gastrointestinal, respiratory, cardiovascular, and urogenital systems [24, 25]. Ultrastructural studies have also revealed that PACAP immunoreactivity is mainly localized near the plasma membrane, in the rough endoplasmic reticulum, in the Golgi’s apparatus, and in the cytoplasmic matrix [2628]. Such a broad distribution of PACAP in several tissues/organs, together with the variety of signalling pathways shown to be activated, poses the peptide in a position suitable to be considered a key drug candidate with the potential to ameliorate a wide spectrum of disorders, including diabetes and its major complications.

Figure 1: 2D chemical structure of full-length PACAP38 (CID 44566111). The chemical structure was retrieved using the publicly available PubChem database source, accessible at https://pubchem.ncbi.nlm.nih.gov/compound/44566111#.

4. PACAP and PAC1 Receptors Distribution in the Retina

PACAP and its high-affinity receptor PAC1 are broadly distributed in a number of organs/systems. Of interest, different studies using rodents have shown that both PACAP and PAC1 immunoreactivity (IR) sites are also detectable in the retina and the nervous tunica of the eye, both known to be highly sensitive to long-lasting glucose insult. Indeed, immunohistochemistry studies have shown that PACAP-like IR is evident in a population of sensory neurons in the rat uvea [29, 30] and in trigeminal ganglion cells [31]. PACAP-IR is also localized at high densities in nonretinal parts of the eye, such as the iris sphincter and the ciliary body [31, 32]. Topographically, specific cell populations were found to be positive for PACAP in retinal tissue samples. In particular, PACAP-positive nerve fibers have been detected in the nerve fiber layer (NFL), the ganglion cell layer (GCL), and the inner plexiform layer (IPL). PACAP-IR was found to be positive in neuronal cell bodies of amacrine and horizontal cells localized in the inner nuclear layer (INL). However, no PACAP-IR has ever been established in rods and cones (photoreceptors) in the outer nuclear layer (ONL) or in neighboring retinal pigmented epithelium [27, 33, 34].

In the IPL, PACAP+ amacrine cell processes make synaptic contacts with retinal ganglion cell (RGC) terminals, as well as amacrine and bipolar cell processes. PACAP+ amacrine cells also establish synaptic contacts with each other. PACAP+ axon terminals establish synapses with ganglion cells, bipolar cells, amacrine cells, and horizontal cells in the GCL, NFL, and IPL.

Studies concerning PAC1 receptor distribution have indicated that binding sites for PACAP and VIP, positively coupled to adenylate cyclase, are expressed in the retina of different mammalian species [18]. PAC1-IR in the retina seems to be mainly detectable in the cell bodies and processes of ganglionic and amacrine cells but not in photoreceptors. At the subcellular level, PAC1 receptors are localized at the plasma membrane, in the rough endoplasmic reticulum, and in the cytoplasmic matrix of RGCs and amacrine cells in the INL. Of note, it has been shown that PAC1 receptor localization not always matches with peptide expression. For instance, in the rat brain, PAC1-IR has been found at high levels in the olfactory bulb, hippocampus, and cerebellar cortex, where only few or no PACAP-containing neurons are identified. However, this may be due to the difficulties associated with detecting antigens in retinal tissue or in nervous tissue in general. However, although it has not been detected in Müller cells in vivo, PAC1+ has been shown in rat primary cultures of Müller cells [35]. For a comprehensive summary depicting PACAP and PAC1 receptor localization to specific cell populations in rodent retina, please refer to Figure 2.

Figure 2: Representative schematic illustration showing PACAP and PAC1 distribution in rodent retina. Immunohistochemical studies have shown that PACAP immunoreactivity (IR) is detectable in nerve fibers (neurites) originating from retinal ganglionic cells as well as in neuronal cell bodies of amacrine and horizontal cells in the inner nuclear layer. No evidence of PACAP-IR has been provided in photoreceptors in the outer nuclear layer (ONL) or in the retinal pigmented epithelium (RPE) [22, 28, 29].

5. PACAP and Diabetic Endothelial Dysfunction

Diabetes is characterized by a high risk of developing chronic complications, with micro- and macrovascular impairments in multiple organs. Today it is well established that increased oxidative stress impairs endothelial function and it is thought to mediate vascular disease.

Vascular function depends upon the balance of oxidant and antioxidant mechanisms. During diabetes, an unbalance between anti-inflammatory and antithrombotic homeostasis in favor of proinflammatory and thrombogenic elements is evident. Heightened oxidative stress and altered expression of a variety of genes related to atherogenesis and angiogenesis have also been described in the vasculature exposed to elevated levels of glucose [6, 7, 3639].

In addition, trophic factor alterations associated with early and late stages of diabetes seem to aggravate hyperglycemia-induced proliferative response, resulting in increased basement membrane thickening and aberrantly regulated vasculogenesis. On the other hand, molecules like PACAP, though being commonly recognized as trophic factors, have demonstrated to also possess opposite biological roles in the vasculature system, most likely depending on the surrounding microenvironment or other coexisting factors, and have been therefore defined as “nonclassic endogenous regulators of angiogenesis” [39]. To support this concept, studies from independent laboratories, including ours, have succeeded to demonstrate that PACAP exerts a rate-limiting effect on cell proliferation under specific pathological conditions replicated in vitro, such as longstanding high glucose exposure in murine microvascular endothelial cells [40] or in aortic smooth muscle cells [41], acting oppositely to the canonical trophic roles. However, the seeming duality of PACAP acting either as a “classic” or “nonclassic” trophic factor molecule should be considered with care. The majority of growth-promoting functions associated with PACAP are complex and context specific, suggesting that the way PACAP responds to “stimuli” depends both on the cell/tissue types, local peptide concentration, bioavailability, and alternative splicing mechanisms but depends also on the nature of the insult itself. In our laboratory, we showed that PACAP was apparently devoid of biological activity on endothelial cells up to 7 days of exposure, whereas the peptide elicited an antiproliferative response after chronic exposure (up to 15 days) to high glucose (25 mM) in the H5V murine microvascular endothelial cell line used [42]. In that same study, we also observed that PACAP and its structurally related homolog vasoactive intestinal peptide (VIP) were unable to induce proliferative activity on their own or to show intrinsic effects on cell viability in these cell lines, although they prevented glucose-induced cell death, possibly by dampening ROS-induced oxidative stress, as indicated by other researchers [43]. It is thus plausible that PACAP may play a dual growth-inhibitory and protective role to arrest the aberrantly activated neovascularization and prevent ROS-mediated apoptosis under hyperglycemic conditions (a schematic representation is depicted in Figure 3).

Figure 3: Proposed model depicting the ameliorative role of PACAP in hyperglycemia-induced endothelial dysfunction: potential involvement of smooth muscle cells through a paracrine mechanism. One of the most devastating complications of persistent hyperglycemia is micro- and macroangiopathy that may determine abnormal vasculogenesis. However, the exact pathogenetic mechanisms are still not well understood. In the proposed scenario, longstanding high glucose levels in the blood stream cause both mechanical (shear stress) or oxidative injury (↑ ROS production) to endothelial cells, whose in turn react by triggering local inflammatory responses, sustained PKC activation, and aberrant angiogenesis (↑ endothelial cell proliferation). PACAP seems to play a homeostatic role in this process. Once released by the neighboring smooth muscle cells (SMCs) it binds to PAC1 receptors expressed by both endothelial cells and SMCs, thereby activating a cAMP-driven signalling cascade that inhibits glucose-induced proliferation of both cell populations and ROS production and dampens PKC function as well as local release of proinflammatory cytokines by infiltrating macrophages.

The importance of PACAP in relationship to circulatory dysfunction caused by long-standing diabetes does not seem to be solely limited to restoring microvasculature, as the combined vasodilatory effects together with the growth-inhbitory functions of the peptide can be extended to the circulatory system in general. In particular, the PACAP homolog VIP has captured scientific interest because of its growth inhibitory properties on smooth muscle cells [44], inferring on its potential effects on diabetes-induced hypertension. It was later discovered that, similarly to VIP, a comparable effect can also be achieved using PACAP, since the main receptor involved is the PACAP/VIP equal affinity receptor VPAC2 [41]. Consistent with the hypotensive effect mediated by VPAC2 receptors, at least a study has demonstrated that PACAP, synthesized in the adrenal medulla, is able to activate VPAC1/VPAC2 receptors in the zona glomerulosa of the adrenal gland, ultimately promoting the systemic release of aldosterone, an endogenous hypotensive hormone [45]. However, other important functions that may be transferred to the circulatory system have been observed, in particular concerning VPAC2 receptor function. Of note, evidence has been provided regarding the potential lipolytic effects exerted by PACAP/VIP-VPAC2 axis in cultured adipocytes [46]. Such activity may have positive repercussions for the search of new strategies to counteract atherogenesis, especially in chronic diabetic patients.

Based on the in vitro and in vivo evidences discussed here, it appears that PACAP, by recruiting different receptors in a cell type-dependent fashion, activates a series of physiological/compensatory responses finalized to reestablish vascular homeostasis. However, further investigations might still be needed to better define the specific actions mediated by each binding receptor, as this will set the stage to develop new highly selective PACAP analogues or receptor agonists encompassing therapeutical activity for the treatment of vascular complications associated with diabetes.

6. Trophic Effects of PACAP on Pancreatic Islets

A hallmark of both types I and II diabetes is the progressive β-cell insufficiency in the pancreas, which results in defects in insulin secretion and hyperglycemia [47, 48]. Pancreatic islet cell apoptosis, induced by various factors such as oxidative stress, inflammation, and toxicity of chronic high blood sugar, results inevitably in a decline of β-cell mass and function in diabetic patients and causes diabetic complications, including diabetic nephropathy, neuropathy, and retinopathy [49, 50]. About two decades ago, PACAP was identified as a novel islet substance that is synthesized and released by pancreatic β-cells. PACAP protein was colocalized to secretory vesicles of insulin and glucagon-containing cells in human and rodent pancreases [51]. In situ hybridization studies have also shown that both PAC1 and VPAC2 receptors are expressed in the β cells, being the predominant PACAP binding receptors in these cells, while VPAC1 receptors were detected only in vessels surrounding the islets [22, 52]. Accumulating in vivo and in vitro studies have shown that PACAP, in an autocrine and/or paracrine manner, produces trophic effects on β-cells. It stimulates the main endocrine pancreatic function (insulin production and release), preserves β-cell responses to glucose, and regulates both proliferation and cell viability [5357]. Studies attempting to establish the exact role of each of the receptors in mediating beneficial activities on β-cell population have taken advantage on genetically engineered mice with either a targeted deletion of the PAC1 receptor gene (PAC1−/−) or of the VPAC2 receptor gene (VPAC2−/−). Either knockout animal model displays reduced insulin response to both gastric and, to a lesser extent, intravenous glucose administration. These mice also display impaired glucose elimination. PAC1 deletion is also associated with a robust reduction of glucose-stimulated insulin secretion, suggesting that PACAP through PAC1 receptors might also play a role in modulating the insulin secretory response to glucose itself. Regarding VPAC2−/− models, although these mice develop normally, they exhibit increased metabolic rate and increased insulin sensitivity, accompanied by reduced body weight due to reduced fat mass. As for PAC1 receptors, these observations suggest that VPAC2 receptors might as well be necessary for physiological insulin secretion [58]. However, despite the common insulinotrophic responses mediated by the two receptors, studies focusing on the diverse potential actions exerted by PACAP are still warranted, since a variety of different intracellular signalling molecules (e.g., cAMP, PKA, ion channels, and MAP kinases) may be differently involved and act in concert in a context-dependent manner to produce variable effects on pancreatic islets during diabetes progression.

7. PACAP Protection in Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the most significant and disabling chronic complications of diabetes mellitus [59]. DR can be generally divided into two clinical stages: nonproliferative and proliferative diabetic retinopathy (PDR). During nonproliferative DR, abnormal permeability and/or nonperfusion of capillaries lead to the formation of microaneurysms and leakage of fluid and solutes into the surrounding retinal tissue which accumulates around the macula, causing diabetic macular oedema (DMO). As DR severity increases, vascular abnormalities (occlusion of retinal capillaries; retinal ischemia) and aberrant neovascularization, a process by which new blood vessels proliferate on the surface of the retina, defining PDR, occur [60]. The tight control of blood glucose levels and blood pressure are essential in preventing or arresting their development. However, these therapeutic objectives are difficult to achieve, even with strict glycemic control, and as a consequence PDR and DMO still appear in a high percentage during the evolution of the disease in patients with both type I and type 2 diabetes [61]. DR has been considered, for many decades, as a microangiopathy disease of the retina with key clinical features, vascular leakage, and preretinal neovascularization, resulting from breakdown of the blood retinal barrier (BRB) [62]. However, there is a mounting evidence to suggest that the pathogenesis of DR may also comprise neuroinflammatory and neuropathic processes, which contribute to visual impairment [63]. Loss of neuroretinal adaptation to the diabetic metabolic environment and neural apoptosis may occur in DR prior to any clinically detectable microvasculopathy, in both human and animal models [64]. In this scenario, hyperglycemia is considered the main culprit for both neural and vascular compromising. The numerous metabolic pathways triggered by hyperglycemia such as the polyol pathway, the hexosamine pathway, the DAG-PKC pathway, advanced glycation end-products beside extracellular glutamate accumulation, oxidative stress, and reduction of neuroprotective factors synthesized by the retina lead to neuronal apoptosis and glial dysfunction, hallmarks of retinal neurodegeneration and BRB breakdown, vasoregression, and altered microvascular system [65]. The presence of neuropeptides in the human retina has mostly been studied by immunohistochemical and chromatographic assays. Neuropeptides are produced from both neural and nonneural cells, and some peptides can also be produced by other extraretinal cell sources. It has now become clear that the neuropeptides described in the retina can be divided in two categories: peptides that promote the development of DR symptoms and others that are able to prevent, delay, or eliminate them. The retinal balance between the neurotoxic and neuroprotective events is crucial to determine neuronal cell fate in the diabetic retina [66]. It is well documented that PACAP and its receptors are expressed in the retina [18, 27, 28] and increasing evidence suggests the retinal protective role of the peptide in different retinal pathologies. A recent study by our research group has shown that, in retina of diabetic rats, an initial upregulation of both PACAP and related receptors preceding morphological evidence of cell death is evident [67]. In that same study, we also showed that PACAP intravitreal treatment downregulated the expression of proapoptotic genes along with other evidences of its protective effects, suggesting an active role for this peptide in counteracting some of the pathogenetic events of DR by different mechanisms, including the apoptotic machinery [68]. Additional studies have confirmed that intraocular injection of PACAP exerts protective effects by increasing anti- and decreasing proapoptotic factors. Indeed, it has been shown that PACAP injections markedly attenuated diabetic retinal injury by increasing the levels of the antiapoptotic p-Akt, pERK1, p-ERK2, PKC, and Bcl-2 signalling, while decreasing the levels of the proapoptotic p-p38MAPK pathway (Figure 4). PACAP also protects ganglion cells and dopaminergic amacrine cells degeneration in experimental diabetes [69, 70]. PACAP emerges as a strong antiapoptotic factor that exerts its effect by acting at different levels of the apoptotic cascade [70, 71]. Further, the broad distribution of the peptide, along with that of its high affinity receptor PAC1, raises the question on whether PACAP-PAC1 axis might also play protective functions in the retina. Consistent with previous evidences from our research group [67], Szabadfi and coworkers [68, 69] have shown that retinal PAC1 receptors are the main receptors to mediate the ameliorative effects on the structural changes caused by streptozotocin in a model of early diabetic retinopathy. It appears though that PACAP acting through PAC1 may indeed trigger protective mechanisms in the retina during diabetic insults. Consistent with such protective function, its potential therapeutic role has also been demonstrated in a model in vitro of DMO, hence showing that PACAP is able to also prevent the disruption of the BRB, mainly by modulating the expression of important tight junctions such as zona occludens-1 (ZO-1) and claudin-1, both essential for the proper functionality of the retinal barrier during diabetes [72].

Figure 4: Schematic diagram showing the main prosurvival/antiapoptotic intracellular pathways activated by PACAP. As apparent from the diagram, the intrinsic apoptotic cascade represents one of the main targets of PACAP to protect cells from death. cAMP, cyclic 3′,5′ adenosine monophosphate; PKA, protein kinase A; PAC1, VPAC1, VPAC2, PACAP-binding receptors; ERK, extracellular regulated protein kinase, Bcl-xL, Bcl-2, antiapoptotic factors; JNK, Janus kinase, Bad, BAX, cytochrome c release, proapoptotic factors; CREB, cAMP responsive element binding protein; CBP, CREB binding protein.

8. PACAP in Diabetic Nephropathy

Alterations in renal function and structure are found even at the onset of diabetes mellitus. Diabetic nephropathy is characterized by initial proteinuria followed by a decline in glomerular filtration rate and ultimate progression to uraemia. Diabetic nephropathy is the leading cause of end-stage renal failure and about 30–40% of patients need renal transplantation [73]. The main clinical features that frequently precede diabetic nephropathy are hypertension and poor glycemic control. Key factors that are involved in diabetic kidney damage are oxidative stress, overproduction of advanced glycation end products (AGE), apoptosis, and inflammation due to the local release of proinflammatory cytokines [74]. Despite the well-established activities of the peptide in many other diabetes complications, the action of PACAP in the kidney of diabetic patients has captured scientific interest only in the past two years. Since the pleiotropic peptide is known to exert anti-inflammatory, antiapoptotic, and antioxidant effects, it appeared reasonable to think that it could be a suitable candidate to also prevent the development or delay the progression of DN. A recent publication by Banki and coworkers identified new molecular mechanisms underlying PACAP nephroprotective properties, including the ability to reduce fibrotic markers, like collagen IV and TGF-β1 in the kidney, or hampering the proapoptotic p38 MAPK pathway [75]. Indeed, other sparse pieces of evidence inferring on the potential beneficial effects of PACAP have been previously described in the kidney using in vitro models, such as vasodilation and renin secretion [76] and protective effects against hydrogen peroxide-induced oxidative stress [72]. In vivo models of diabetic nephropathy have also proven the protective role of PACAP in this pathological condition. Its ameliorative effects against high glucose-driven kidney impairment seem to be in part due to inhibition of apoptotic, fibrotic, and oxidative pathways, paralleled by anti-inflammatory properties of the peptide [75, 77]. Although promising, these investigations may be considered as proof-of-concept studies and will require more in-depth studies to really prove the potential therapeutic validity of PACAP against this specific diabetes-associated complication.

9. Neuropathy and Future PACAP Application?

A further severe complication in most cases secondary to angiopathy is diabetic neuropathy, which affects the peripheral nervous system. Over half of all patients affected by diabetes develop some form of neuropathy, resulting in sensory loss, pain, and autonomic dysfunction. These manifestations of neuropathy can severely reduce a patient’s quality of life. As for the previous complications discussed above, duration of diabetes and glycemic control are important risk factors for neuropathy in both patients with type 1 and type 2 diabetes [78]. Actually, no therapy is approved by regulatory bodies in Europe and the United States for diabetic degenerative neuropathy. The only strategy adopted is the maintenance of normoglycemia, but current treatments for pain management are not effective and/or do not target the causes of diabetes-induced pain. The lack of therapies largely reflects the absence of suitable animal models to study the exact causes of neuropathy [79]. In this scenario, PACAP could be considered a good candidate target considering its numerous beneficial properties. It can circulate in the brain and to some extent cross the blood brain barrier. In particular, the shorter form (PACAP 27) is transported into the brain by transmembrane diffusion, a nonsaturable mechanism, while the uptake of PACAP 38 into the brain occurs through a saturable mechanism. However, to date no significant data has been produced in relationship to this diabetic complication. A plausible reason to explain such an apparent lack of interest on the use of PACAP to treat or prevent diabetic neuropathy could be related to its relatively low bioavailability in the brain. In fact, when administered systemically, native PACAP is rapidly hydrolyzed by the ubiquitous enzyme dipeptidyl-peptidase IV (DPP IV) to form PACAP (3–38) or PACAP (5–38), which are two shorter forms of the peptide with an antagonist activity on PAC1 receptors in most cases [80]. The degradation by DPP IV in the blood circulation also results in the poor metabolic stability with short half-life between 2 and 10 min after PACAP is injected into mice or human [81]. N-terminal truncation of PACAP by removal of the first five amino acids results in a potent PAC1 antagonist that retains the ability to bind PACAP binding sites, does not stimulate adenylate cyclase, and inhibits the ability of PACAP to stimulate adenylate cyclase. With this in mind, the beneficial results of PACAP treatment may be present only when the peptide is administered locally, and this is a great limitation to its clinical use. Current efforts by research laboratories and biotechnologies are now being put to develop a more stable form of the peptide that still retains its ability to cross the blood brain barrier and reach the central or peripheral nervous system. However, at least a research group has succeeded in developing a novel cyclopeptide from the cyclization of PACAP (1–5) that possesses potent activity towards PAC1 and is able to attenuate experimentally-induced diabetes and ganglionic cell death [82, 83], suggesting that advances have been made to overcome the problems associated with poor peptide availability. An alternative objective being pursued is to increase the average half-life of the peptide once systemically injected. The strategy could be by blocking DPP IV enzymatic activity on PACAP through the coadministration of a specific inhibitory agent. Interestingly, metformin, an oral agent commonly prescribed to treat type 2 diabetes involved in the reduction of hepatic glucose production and/or insulin resistance, has shown to also decrease plasma DPP IV activity, limiting the inactivation of exogenously administered peptides [84]. In this regard, Ahrén and Hughes (2005) [85] have elegantly demonstrated that another DDP IV inhibitor, namely, valine-pyrrolidide, when administered through gastric gavage, increases insulin response to PACAP and other substrates of the enzyme, opening new perspectives on the potential clinical validity of the peptide.

10. Conclusions

The present review summarizes the findings on the neuroprotective potential of PACAP in major diabetes complications. Based on these data, PACAP emerges as a powerful and promising candidate in the treatment of those pathological conditions associated with long-lasting diabetes. From the present review it arises that diabetic complications are the main consequence of significant changes in vascular structure and function, along with other metabolic alterations. PACAP appears to be able to effectively counteract and/or prevent the majority of these changes, making it a potentially valuable candidate to treat diabetes complication. Unfortunately, a major hurdle that has significantly limited PACAP therapeutic use in T2D-related injuries depends on the rapid hydrolysis of the peptide occurring when injected systemically. Future efforts are therefore necessary to develop a peptide analogue which is more stable, can easily cross human biological barriers (i.e., blood and retinal brain barrier) to bind its receptors in affected organs/systems, and possesses adequate pharmacokinetics. Alternatively, other routes could be to take advantage of new generation viruses for PACAP gene delivery to treat this still unmet medical need, but further studies in this direction are yet to be carried out to exclude any possible associated risk.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Rubina Marzagalli and Soraya Scuderi contributed equally to this work.

Acknowledgments

These experiments were supported by the Department of Biomedical Sciences and Biotechnologies, School of Medicine, University of Catania, Italy (National Grant PON 01_00110). The authors would like to thank Mr P. Asero for his technical support.

References

  1. H. King, R. E. Aubert, and W. H. Herman, “Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections,” Diabetes Care, vol. 21, no. 9, pp. 1414–1431, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Donnelly, A. M. Emslie-Smith, I. D. Garnder, and A. D. Morris, “ABC of arterial and venous disease. Vascular complications of diabetes,” British Medical Journal, vol. 320, no. 7241, pp. 1062–1066, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Nathan, P. A. Cleary, J.-Y. C. Backlund et al., “Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2643–2653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Casanova, F. J. Hughes, and P. M. Preshaw, “Diabetes and periodontal disease: a two-way relationship,” British Dentistry Journal, vol. 217, no. 8, pp. 433–437, 2014. View at Publisher · View at Google Scholar
  6. L. Feng, C. Matsumoto, A. Schwartz, A. M. Schmidt, D. M. Stern, and J. Pile-Spellman, “Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis,” Diabetes Care, vol. 28, no. 2, pp. 379–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Crimi, L. J. Ignarro, and C. Napoli, “Microcirculation and oxidative stress,” Free Radical Research, vol. 41, no. 12, pp. 1364–1375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Miyata, A. Arimura, R. R. Dahl et al., “Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells,” Biochemical and Biophysical Research Communications, vol. 164, no. 1, pp. 567–574, 1989. View at Publisher · View at Google Scholar · View at Scopus
  9. N. M. Sherwood, S. L. Krueckl, and J. E. McRory, “The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily,” Endocrine Reviews, vol. 21, no. 6, pp. 619–670, 2000. View at Publisher · View at Google Scholar
  10. M. Laburthe, A. Couvineau, and J.-C. Marie, “VPAC receptors for VIP and PACAP,” Receptors and Channels, vol. 8, no. 3-4, pp. 137–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Elekes, K. Sandor, A. Moricz et al., “Pituitary adenylate cyclase-activating polypeptide plays an anti-inflammatory role in endotoxin-induced airway inflammation: in vivo study with gene-deleted mice,” Peptides, vol. 32, no. 7, pp. 1439–1446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Reglodi, P. Kiss, K. Szabadfi et al., “PACAP is an endogenous protective factor-insights from PACAP-deficient mice,” Journal of Molecular Neuroscience, vol. 48, no. 3, pp. 482–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Castorina, A. Tiralongo, S. Giunta, M. L. Carnazza, G. Rasi, and V. D'Agata, “PACAP and VIP prevent apoptosis in schwannoma cells,” Brain Research, vol. 1241, pp. 29–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Giunta, A. Castorina, A. Adorno, V. Mazzone, M. L. Carnazza, and V. D'Agata, “PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells,” Neuropeptides, vol. 44, no. 1, pp. 45–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Castorina, S. Giunta, S. Scuderi, and V. D'Agata, “Involvement of PACAP/ADNP signaling in the resistance to cell death in malignant peripheral nerve sheath tumor (MPNST) cells,” Journal of Molecular Neuroscience, vol. 48, no. 3, pp. 674–683, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Castorina, J. A. Waschek, R. Marzagalli, V. Cardile, F. Drago, and H. Vaudry, “PACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like cultures,” PLOS ONE, vol. 10, no. 2, Article ID e0117799, 2015. View at Publisher · View at Google Scholar
  17. S. Giunta, A. Castorina, R. Marzagalli et al., “Ameliorative effects of PACAP against cartilage degeneration. Morphological, immunohistochemical and biochemical evidence from in vivo and in vitro models of rat osteoarthritis,” International Journal of Molecular Sciences, vol. 16, no. 3, pp. 5922–5944, 2015. View at Publisher · View at Google Scholar
  18. V. D'Agata and S. Cavallaro, “Functional and molecular expression of PACAP/VIP receptors in the rat retina,” Molecular Brain Research, vol. 54, no. 1, pp. 161–164, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Somogyvári-Vigh, J. Svoboda-Teet, S. Vigh, and A. Arimura, “Is an intravenous bolus injection required prior to initiating slow intravenous infusion of PACAP38 for prevention of neuronal death induced by global ischemia? The possible presence of a binding protein for PACAP38 in blood,” Annals of the New York Academy of Sciences, vol. 865, pp. 595–600, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Shioda, H. Ohtaki, T. Nakamachi et al., “Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment,” Annals of the New York Academy of Sciences, vol. 1070, pp. 550–560, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Ohtaki, T. Nakamachi, K. Dohi, and S. Shioda, “Role of PACAP in ischemic neural death,” Journal of Molecular Neuroscience, vol. 36, no. 1–3, pp. 16–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. S. Winzell and B. Ahrén, “Role of VIP and PACAP in islet function,” Peptides, vol. 28, no. 9, pp. 1805–1813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Broca, J. Quoyer, S. Costes et al., “β-Arrestin 1 is required for PAC1 receptor-mediated potentiation of long-lasting ERK1/2 activation by glucose in pancreatic β-cells,” The Journal of Biological Chemistry, vol. 284, no. 7, pp. 4332–4342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Ødum, L. J. Petersen, P. S. Skov, and L. B. Ebskov, “Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells,” Inflammation Research, vol. 47, no. 12, pp. 488–492, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. M. M. Heimesaat, I. R. Dunay, S. Schulze et al., “Pituitary adenylate cyclase-activating polypeptide ameliorates experimental acute ileitis and extra-intestinal sequelae,” PLoS ONE, vol. 9, no. 9, Article ID e108389, 2014. View at Publisher · View at Google Scholar
  26. H. Terubayashi, T. Tsuto, K. Fukui et al., “VIP (vasoactive intestinal polypeptide)-like immunoreactive amacrine cells in the retina of the rat,” Experimental Eye Research, vol. 36, no. 5, pp. 743–749, 1983. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Izumi, T. Seki, S. Shioda, C.-J. Zhou, A. Arimura, and R. Koide, “Ultrastructural localization of PACAP immunoreactivity in the rat retina,” Annals of the New York Academy of Sciences, vol. 921, pp. 317–320, 2000. View at Google Scholar · View at Scopus
  28. T. Seki, S. Izumi, S. Shioda, C. J. Zhou, A. Arimura, and R. Koide, “Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR,” Annals of the New York Academy of Sciences, vol. 921, pp. 366–369, 2000. View at Google Scholar · View at Scopus
  29. K. Moller, Y.-Z. Zhang, R. Hakanson et al., “Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence,” Neuroscience, vol. 57, no. 3, pp. 725–732, 1993. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Mulder, R. Uddman, K. Moller et al., “Pituitary adenylate cyclase activating polypeptide expression in sensory neurons,” Neuroscience, vol. 63, no. 1, pp. 307–312, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Onali and M. C. Olianas, “PACAP is a potent and highly effective stimulator of adenylyl cyclase activity in the retinas of different mammalian species,” Brain Research, vol. 641, no. 1, pp. 132–134, 1994. View at Publisher · View at Google Scholar · View at Scopus
  32. Z.-Y. Wang, P. Alm, and R. Håkanson, “Distribution and effects of pituitary adenylate cyclase-activating peptide in the rabbit eye,” Neuroscience, vol. 69, no. 1, pp. 297–308, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Seki, S. Shioda, D. Ogino, Y. Nakai, A. Arimura, and R. Koide, “Distribution and ultrastructural localization of a receptor for pituitary adenylate cyclase activating polypeptide and its mRNA in the rat retina,” Neuroscience Letters, vol. 238, no. 3, pp. 127–130, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Seki, S. Shioda, Y. Nakai, A. Arimura, and R. Koide, “Distribution and ultrastractural localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor in the rat retina,” Annals of the New York Academy of Sciences, vol. 865, pp. 408–411, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Seki, Y. Hinohara, C. Taki et al., “PACAP stimulates the release of interleukin-6 in cultured rat Müller cells,” Annals of the New York Academy of Sciences, vol. 1070, pp. 535–539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Di Paolo, L. Gesualdo, E. Ranieri, G. Grandaliano, and F. P. Schena, “High glucose concentration induces the overexpression of transforming growth factor-β through the activation of a platelet-derived growth factor loop in human mesangial cells,” The American Journal of Pathology, vol. 149, no. 6, pp. 2095–2106, 1996. View at Google Scholar · View at Scopus
  37. H. Ogita and J. K. Liao, “Endothelial function and oxidative stress,” Endothelium, vol. 11, no. 2, pp. 123–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. O. I. Stenina, “Regulation of vascular genes by glucose,” Current Pharmaceutical Design, vol. 11, no. 18, pp. 2367–2381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Ribatti, M. T. Conconi, and G. G. Nussdorfer, “Nonclassic endogenous regulators of angiogenesis,” Pharmacological Reviews, vol. 59, no. 2, pp. 185–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Castorina, S. Giunta, V. Mazzone, V. Cardile, and V. D'Agata, “Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells,” Peptides, vol. 31, no. 12, pp. 2276–2283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. R.-C. Hilaire, S. N. Murthya, P. J. Kadowitza, and J. R. Jeter Jr., “Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation,” Peptides, vol. 31, no. 8, pp. 1517–1522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Garlanda, C. Parravicini, M. Sironi et al., “Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7291–7295, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Rácz, B. Gasz, B. Borsiczky et al., “Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis,” General and Comparative Endocrinology, vol. 153, no. 1–3, pp. 115–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Hultgårdh-Nilsson, J. Nilsson, B. Jonzon, and C.-J. Dalsgaard, “Growth-inhibitory properties of vasoactive intestinal polypeptide,” Regulatory Peptides, vol. 22, no. 3, pp. 267–274, 1988. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Mazzocchi, L. K. Malendowicz, G. Neri et al., “Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland,” International Journal of Molecular Medicine, vol. 9, no. 3, pp. 233–243, 2002. View at Google Scholar · View at Scopus
  46. L. Åkesson, B. Ahrén, G. Edgren, and E. Degerman, “VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes,” Endocrinology, vol. 146, no. 2, pp. 744–750, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. C. J. Rhodes, “Type 2 diabetes—a matter of β-cell life and death?” Science, vol. 307, no. 5708, pp. 380–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. H. E. Thomas and T. J. Biden, “Bad news for β-cell apoptosis,” Diabetes, vol. 58, no. 8, pp. 1725–1727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Mathis, L. Vence, and C. Benoist, “β-cell death during progression to diabetes,” Nature, vol. 414, no. 6865, pp. 792–798, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. R. P. Robertson and J. S. Harmon, “Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet β cell,” Free Radical Biology and Medicine, vol. 41, no. 2, pp. 177–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. G. M. Portela-Gomes, A. Lukinius, O. Ljungberg, S. Efendic, B. Ahrén, and S. M. Abdel-Halim, “PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas: evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets,” Regulatory Peptides, vol. 113, no. 1–3, pp. 31–39, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Inagaki, H. Yoshida, M. Mizuta et al., “Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 7, pp. 2679–2683, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Yada, M. Sakurada, H. Ishihara et al., “Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats,” Journal of Physiology, vol. 505, no. 2, pp. 319–328, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Yamamoto, H. Hashimoto, S. Tomimoto et al., “Overexpression of PACAP in transgenic mouse pancreatic β-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes,” Diabetes, vol. 52, no. 5, pp. 1155–1162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Onoue, J. Hanato, and S. Yamada, “Pituitary adenylate cyclase-activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression,” The FEBS Journal, vol. 275, no. 22, pp. 5542–5551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Vaudry, A. Falluel-Morel, S. Bourgault et al., “Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery,” Pharmacological Reviews, vol. 61, no. 3, pp. 283–357, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Sakurai, N. Shintani, A. Hayata, H. Hashimoto, and A. Baba, “Trophic effects of PACAP on pancreatic islets: a mini-review,” Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 3–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Ahrén, “Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system,” Annals of the New York Academy of Sciences, vol. 1144, pp. 28–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. N. G. Congdon, D. S. Friedman, and T. Lietman, “Important causes of visual impairment in the world today,” Journal of the American Medical Association, vol. 290, no. 15, pp. 2057–2060, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Williams, M. Airey, H. Baxter, J. Forrester, T. Kennedy-Martin, and A. Girach, “Epidemiology of diabetic retinopathy and macular oedema: a systematic review,” Eye, vol. 18, no. 10, pp. 963–983, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. Q. Mohamed, M. C. Gillies, and T. Y. Wong, “Management of diabetic retinopathy: a systematic review,” Journal of the American Medical Association, vol. 298, no. 8, pp. 902–916, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Kolár, “Patophysiology of diabetic retinopathy,” Vnitřní lékařství, vol. 59, no. 3, pp. 173–176, 2013. View at Google Scholar
  63. D. A. Antonetti, A. J. Barber, S. K. Bronson et al., “Diabetic retinopathy: seeing beyond glucose-induced microvascular disease,” Diabetes, vol. 55, no. 9, pp. 2401–2411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Zhang, N. Wang, G. R. Barile, S. Bao, and M. Gillies, “Diabetic retinopathy: neuron protection as a therapeutic target,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 7, pp. 1525–1529, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Gábriel, “Neuropeptides and diabetic retinopathy,” British Journal of Clinical Pharmacology, vol. 75, no. 5, pp. 1189–1201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Giunta, A. Castorina, C. Bucolo, G. Magro, F. Drago, and V. D'Agata, “Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats,” Peptides, vol. 37, no. 1, pp. 32–39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Szabadfi, T. Atlasz, P. Kiss et al., “Protective effects of the neuropeptide PACAP in diabetic retinopathy,” Cell and Tissue Research, vol. 348, no. 1, pp. 37–46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Szabadfi, A. Szabo, P. Kiss et al., “PACAP promotes neuron survival in early experimental diabetic retinopathy,” Neurochemistry International, vol. 64, no. 1, pp. 84–91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Somogyvári-Vigh and D. Reglodi, “Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide,” Current Pharmaceutical Design, vol. 10, no. 23, pp. 2861–2889, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Seaborn, O. Masmoudi-Kouli, A. Fournier, H. Vaudry, and D. Vaudry, “Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis,” Current Pharmaceutical Design, vol. 17, no. 3, pp. 204–214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Scuderi, A. G. D'Amico, A. Castorina, R. Imbesi, M. L. Carnazza, and V. D'Agata, “Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction,” Peptides, vol. 39, no. 1, pp. 119–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. C. E. Mogensen, C. K. Christensen, and E. Vittinghus, “The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy,” Diabetes, vol. 32, no. 2, pp. 64–78, 1983. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Gnudi, “Cellular and molecular mechanisms of diabetic glomerulopathy,” Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2642–2649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Banki, K. Kovacs, D. Nagy et al., “Molecular mechanisms underlying the nephroprotective effects of PACAP in diabetes,” Journal of Molecular Neuroscience, vol. 54, no. 3, pp. 300–309, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Reglodi, P. Kiss, G. Horvath et al., “Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney,” Neuropeptides, vol. 46, no. 2, pp. 61–70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Banki, P. Degrell, P. Kiss et al., “Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy,” Peptides, vol. 42, pp. 125–130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993.
  79. N. A. Calcutt, M. E. Cooper, T. S. Kern, and A. M. Schmidt, “Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials,” Nature Reviews Drug Discovery, vol. 8, no. 5, pp. 417–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. B. D. Green, N. Irwin, and P. R. Flatt, “Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential,” Peptides, vol. 27, no. 6, pp. 1349–1358, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Li, J. L. Maderdrut, J. J. L. Lertora, and V. Batuman, “Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study,” Peptides, vol. 28, no. 9, pp. 1891–1895, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Yu, J. Wang, J. Li et al., “A novel cyclopeptide from the cyclization of PACAP(1-5) with potent activity towards PAC1 attenuates STZ-induced diabetes,” Peptides, vol. 31, no. 6, pp. 1062–1067, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Cheng, Y. Ding, R. Yu, J. Chen, C. Wu, and R. Linden, “Neuroprotection of a novel cyclopeptide C*HSDGIC* from the cyclization of PACAP (1–5) in cellular and rodent models of retinal ganglion cell apoptosis,” PLoS ONE, vol. 9, no. 10, Article ID e108090, 2014. View at Publisher · View at Google Scholar
  84. B. D. Green, N. Irwin, N. A. Duffy, V. A. Gault, F. P. M. O'Harte, and P. R. Flatt, “Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1,” European Journal of Pharmacology, vol. 547, no. 1–3, pp. 192–199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. B. Ahrén and T. E. Hughes, “Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice,” Endocrinology, vol. 146, no. 4, pp. 2055–2059, 2005. View at Publisher · View at Google Scholar · View at Scopus